This years American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented major advances in hematology,…
Browsing: Acute Lymphoblastic Leukemia
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, showcased the most cutting-edge data…
Athough new molecules have advanced the treatment of Hodgkin lymphoma considerably in recent years, research is still ongoing to achieve…
Although the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, may not have had…
The monitoring of minimal residual disease (MRD) is important in predicting relapse and giving a more sensitive measurement to clinicians…
Although little is currently known about the mechanisms of resistance to venetoclax, researchers are constantly looking for new drugs that…
In chronic lymphocytic leukemia (CLL), venetoclax has established itself as one of the most effective monotherapies in certain contexts. Speaking…
Venetoclax and ibrutinib are two relatively new drugs being used for the treatment of chronic lymphocytic leukemia (CLL), and although…
Social media platforms, such as Twitter, are a staple of the modern world and facilitate communication between people from all…
CAR T-cell therapy has emerged as a highly promising cancer treatment in recent years, with patient’s own cells being modified…
As age increases, the likelihood of a patients with hematological malignancies having further complications and comorbidities increases. Speaking from the…
Immunotherapy has been a primary area of focus in lymphoma research in recent years, with treatments looking to stimulate and…
In this activity, Congress Chair Dr. Morton Coleman and CLL Session Co-Chair Dr. Richard R. Furman discuss highlights of the…
In this Key Insights activity, Congress Chair Dr. Morton Coleman and Lymphoma Session Co-Chair Dr. John Leonard discuss highlights of…
Updates from the highly anticipated Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) were presented at the…
In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss highlights of the first day of Lymphoma &…
There has historically been less novel agents being tested and moving into the clinic for AML. Now, there has been…
Venetoclax combinations have shown excellent results in chronic lymphocytic leukemia (CLL), but are now, excitingly, displaying fantastic preliminary outcomes in…
Although a key skill of nursing is communication with patients and the multidisciplinary team, ensuring good communication channels within and…
Nursing is a demanding job, with the many responsibilities and patients meaning that nurses are often under considerable time pressure.…
Immunotherapies can come with a range of toxicities that require the appropriate management by acute oncology services. In this interview,…
As novel immunotherapies are introduced into practice, centers need to implement new protocols and educate staff in order to ensure…
Immunotherapies can induce a range of common, as well as rare, side effects. These may be difficult for healthcare professionals…
Collating data and communicating center experiences is essential to ensure that the best standard of care is provided to patients…
Dr. Susanne Osanto discusses the use of chemotherapy plus androgen deprivation therapy (ADT) for newly diagnosed men with advanced stage…
There are many intricacies surrounding the introduction of biosimilars. Here, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH),…
“During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm,…
“During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm,…
“Peter Johnson, BA, MB BChir, MA, MRCP, MD, FRCP from Southampton General Hospital, Southampton, UK, summarises the challenges of cancer…
David Irvine from the Beatson Institute, Glasgow, UK outlines his presentation on cellular advances in hematological oncology given at the…
Having academics who also work in the clinic has a wide range of benefits. In this interview, Naomi Farrington, PhD,…
Elderly cancer patients are likely to have comorbidities and more complex treatment needs, which can result in certain treatments not…
Elderly patients comprise the majority of cancer cases; however, they are often overlooked in many facets of oncology research and…
Pharmacists have an excellent knowledge of drugs and are an essential part of the multidisciplinary healthcare team. Excitingly, they are…
Nurses have a high level of contact with individual patients, which enables them to have a unique perspective on their…
The official recommendations are that patients taking oral systemic anti-cancer therapy (SACT) receive the same level as care as those…
The debate at the UK Oncology Nursing Society (UKONS) Annual Conference 2017 in Harrogate, UK, focused on highlighting the importance…
Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS)…
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Model systems, including patient specimens and murine organisms, are very important for multiple myeloma (MM) research. Speaking from the Myeloma…
There is a plethora of therapies available for multiple myeloma (MM). In this insightful panel discussion at the Myeloma 2017…
There are currently many exciting novel therapeutics and combination therapies undergoing clinical trials for use in multiple myeloma (MM) patients.…
A key finding of a recent Bloodwise study into the specific needs of hematological cancer patients highlighted the importance of…
Immunotherapy is a growing treatment area for cancer, with a lot of hype in the mainstream media. In this interview,…
Immunotherapy has received a lot of coverage as a revolutionary cancer treatment, in both the medical community and in the…
In recent years, molecular tests have emerged that can help provide information about cancers, such as determining what type of…
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as…
It is critical that cancer patients report the side effects of their treatments, whether chemotherapy or immunotherapy, as early as…
With age being the biggest risk factor for cancer, and an ageing population in the UK, the NHS is having…
Recent studies presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK have identified multiple…